Despite what some headlines may suggest, no drug has actually been approved by the FDA specifically for alcoholic liver disease — or more precisely, alcohol-associated hepatitis — as of early 2026. The condition remains one of the largest unmet needs in liver medicine, with roughly 30 percent of hospitalized patients dying within 90 days even with the best available care. What has happened is that a promising candidate called larsucosterol (formerly known as DUR-928) has received both Breakthrough Therapy and Fast Track designations from the FDA, which speeds up the review process but does not constitute an approval.
If you encountered a headline claiming otherwise, it likely conflated these regulatory milestones with an actual green light, or confused larsucosterol’s progress with the March 2024 approval of resmetirom (brand name Rezdiffra) for MASH — a non-alcoholic fatty liver condition that is an entirely different disease. This distinction matters enormously for the millions of people affected by alcohol-related liver damage and for the families navigating care decisions alongside them. For a dementia care audience in particular, the overlap is worth understanding: chronic liver disease and heavy alcohol use are both independent risk factors for cognitive decline, and the systemic inflammation that characterizes alcohol-associated hepatitis can accelerate neurological damage. What follows is a thorough look at where larsucosterol stands, why the current treatment landscape is so barren, what other drugs are in the pipeline, and what patients and caregivers should actually know right now.
Table of Contents
- What Is the Alcoholic Liver Disease Drug That Has Been in Trials for Years?
- Why Are There Zero Approved Treatments for Alcohol-Associated Hepatitis?
- How Larsucosterol’s Trial Results Complicated the Picture
- What Patients and Caregivers Should Know About Current Treatment Options
- The Confusion Between Alcoholic and Non-Alcoholic Liver Disease Approvals
- Other Drugs in the Pipeline and Why Options Remain Limited
- What the Next Two Years Could Mean for Patients
- Conclusion
- Frequently Asked Questions
What Is the Alcoholic Liver Disease Drug That Has Been in Trials for Years?
Larsucosterol is an endogenous sulfated oxysterol — a molecule the body naturally produces in small amounts — that modulates lipid metabolism, inflammation, and cell survival pathways in the liver. Developed originally by DURECT Corporation, the drug entered the spotlight after receiving FDA Breakthrough Therapy designation for alcohol-associated hepatitis, a recognition reserved for treatments that show substantial improvement over existing options for serious conditions. In September 2025, Bausch Health completed its acquisition of DURECT for approximately $63 million upfront, or $1.75 per share, taking over the drug’s development pipeline and signaling that a major pharmaceutical company sees real commercial potential in this space. The drug’s Phase 2b trial, known as AHFIRM, generated mixed but intriguing results. It did not meet its primary endpoint of reducing mortality or the need for liver transplant at 90 days across the full study population. However, among U.S.
patients — who made up 76 percent of trial participants — the 30 mg and 90 mg doses showed 57 percent and 58 percent mortality reductions compared to placebo, respectively. Those are striking numbers in a disease where nothing else has come close to that kind of efficacy, and they formed the basis for moving forward into Phase 3 testing. The Phase 3 registrational trial has been designed to enroll 200 U.S. patients with a 90-day survival primary endpoint, a focused approach that reflects the strongest signal from the earlier data. Topline results are expected within roughly two years of the trial’s initiation. If those results hold up, larsucosterol could become the first drug ever approved for this indication — but that approval is still years away, not something that has already happened.
Why Are There Zero Approved Treatments for Alcohol-Associated Hepatitis?
The absence of any FDA-approved therapy for alcohol-associated hepatitis is not for lack of need. It reflects the staggering difficulty of treating a condition driven by ongoing organ damage in patients whose disease is intertwined with addiction, malnutrition, and often limited access to healthcare. Clinical trials in this population face high dropout rates, ethical complexity around placebo arms when patients are critically ill, and the confounding variable of whether participants continue drinking during the study period. Corticosteroids, specifically prednisolone, have been the de facto first-line treatment for decades despite never receiving a formal FDA indication for this use. They reduce short-term inflammation but do not address the underlying liver damage, and their benefit is modest — that 30 percent mortality rate at 90 days persists even with steroid treatment.
Pentoxifylline, a second-line option, has shown even less convincing evidence of benefit in recent large trials. Beyond these, the cornerstone of management remains alcohol abstinence and nutritional support, which are essential but insufficient for patients with severe disease. However, if a patient presents with mild alcohol-associated hepatitis rather than the severe form, the calculus changes. Mild cases often resolve with abstinence and supportive care alone, and the risk-benefit profile of steroids may not favor treatment. The critical gap is in severe disease — defined by a Maddrey discriminant function score above 32 — where patients are dying at alarming rates and physicians have essentially nothing to offer beyond supportive measures and hope.
How Larsucosterol’s Trial Results Complicated the Picture
Clinical trials rarely produce clean, unambiguous results, and larsucosterol’s Phase 2b AHFIRM trial is a case study in how to interpret nuanced data. The headline finding — failure to meet the primary endpoint — would normally signal trouble. But the pre-specified subgroup analysis of U.S. patients told a different story, with those dramatic mortality reductions of 57 to 58 percent in the two higher dose groups. The discrepancy between the overall population and the U.S. subgroup likely reflects differences in standard of care, patient demographics, and disease severity across the international trial sites. This is where scientific interpretation gets tricky and where headlines can mislead.
A subgroup analysis, even one that was pre-specified, does not carry the same statistical weight as a primary endpoint hit. The FDA recognized the promise in the data — hence the Breakthrough Therapy and Fast Track designations — but appropriately required a new Phase 3 trial focused specifically on the population where the drug appeared to work. That trial’s design, enrolling 200 U.S. patients with the 90-day survival endpoint, is essentially a confirmation study. For patients and caregivers following this story, the practical takeaway is cautious optimism tempered by realism. Promising Phase 2 subgroup results fail to replicate in Phase 3 trials more often than they succeed. The drug’s mechanism — targeting lipid metabolism, inflammation, and cell survival simultaneously — is scientifically plausible, but biology does not always cooperate with plausibility.
What Patients and Caregivers Should Know About Current Treatment Options
For someone dealing with alcohol-associated hepatitis today, the treatment conversation with a hepatologist will be straightforward and somewhat discouraging. If the disease is severe, corticosteroids will likely be recommended, with the understanding that they help some patients but fail many others. The Lille score, measured after seven days of steroid treatment, helps determine whether the drugs are working — a score above 0.45 suggests the steroids are not effective and should be stopped to avoid their side effects, which include increased infection risk. The comparison between corticosteroids and supportive care alone highlights a genuine tradeoff. Steroids may improve 28-day survival in responders, but they carry risks of infection, hyperglycemia, and gastrointestinal bleeding in a patient population that is already critically ill and often malnourished.
Pentoxifylline, once considered a reasonable alternative, showed no survival benefit over placebo in the large STOPAH trial, and many hepatologists have moved away from using it. Liver transplantation remains the definitive treatment for patients who do not recover, but strict sobriety requirements and organ scarcity limit access. For caregivers in the dementia space, this matters because chronic alcohol-related liver disease and its treatments have cognitive consequences. Hepatic encephalopathy — confusion and cognitive impairment caused by the liver’s failure to clear toxins — can mimic or worsen dementia symptoms. Distinguishing between hepatic encephalopathy and neurodegenerative dementia is critical and frequently missed, particularly in older adults with a history of heavy drinking.
The Confusion Between Alcoholic and Non-Alcoholic Liver Disease Approvals
Much of the confusion around a supposed alcoholic liver disease drug approval likely stems from the March 2024 approval of resmetirom, sold under the brand name Rezdiffra, for MASH — metabolic dysfunction-associated steatohepatitis. MASH is a non-alcoholic fatty liver disease driven primarily by metabolic factors like obesity, insulin resistance, and dyslipidemia. It is not the same condition as alcohol-associated hepatitis, and resmetirom has no indication, evidence base, or biological rationale for treating alcohol-related liver damage. The naming conventions in liver disease have undergone significant revision in recent years, which has added to public confusion.
What was previously called NASH (non-alcoholic steatohepatitis) is now MASH, and the broader category of non-alcoholic fatty liver disease (NAFLD) has been renamed MASLD (metabolic dysfunction-associated steatotic liver disease). These changes were meant to reduce stigma and improve diagnostic precision, but they have also muddied public understanding of which drugs treat which conditions. The warning here is direct: do not assume that a drug approved for one type of liver disease will work for another. The underlying mechanisms are different, the patient populations are different, and the clinical trial evidence does not cross over. If you or a loved one has alcohol-associated hepatitis, resmetirom is not a treatment option, and any source claiming otherwise is either confused or misleading.
Other Drugs in the Pipeline and Why Options Remain Limited
Beyond larsucosterol, the pipeline for alcohol-associated hepatitis is thin. Aldeyra Therapeutics tested ADX-629, a reactive aldehyde species inhibitor, in a Phase 2 trial for mild-to-moderate alcohol-associated hepatitis and reported positive results. However, the company subsequently discontinued clinical development of the drug, leaving further testing to investigator-sponsored efforts with no clear timeline or funding commitment.
This pattern — early promise followed by abandonment — has repeated itself multiple times in this therapeutic area, reflecting both the difficulty of the science and the historically limited commercial incentive. That incentive picture may be shifting. Market analysts project the alcoholic hepatitis treatment market will reach $1.06 billion by 2034, a figure that reflects the enormous patient population and the premium pricing that a first-in-class therapy could command. Bausch Health’s acquisition of DURECT suggests at least one major company is betting that this market will materialize.
What the Next Two Years Could Mean for Patients
The timeline to watch is larsucosterol’s Phase 3 trial readout, expected roughly two years from the trial’s initiation. If the drug replicates the mortality reductions seen in U.S. patients during Phase 2b, the path to approval could be relatively swift given its existing Breakthrough Therapy and Fast Track designations.
These regulatory tools can compress the review timeline from the standard 10 to 12 months down to as little as six months, and they allow for rolling submission of data rather than waiting for a complete application package. For patients, caregivers, and clinicians who have been managing this disease with inadequate tools for decades, the prospect of a first approved therapy is significant but not yet certain. The responsible approach is to stay informed, maintain current best practices around abstinence support and nutritional optimization, and recognize that breakthrough designations are a signal of promise, not a guarantee of success. If and when larsucosterol or another candidate crosses the finish line, it will represent a genuine watershed moment in hepatology — but that moment has not arrived yet.
Conclusion
The story of alcoholic liver disease drug development is one of decades of failure, a barren treatment landscape, and now a single promising candidate that has generated real but incomplete evidence. Larsucosterol’s journey from an obscure oxysterol compound to the most advanced drug ever tested for alcohol-associated hepatitis is notable, but the critical Phase 3 data that would support an actual FDA approval is still years away. No drug has been approved for this indication as of March 2026, and anyone claiming otherwise is misreading the regulatory milestones or confusing this condition with non-alcoholic liver diseases like MASH.
For caregivers and families navigating the intersection of liver disease, alcohol use, and cognitive decline, the practical next steps remain the same: work closely with hepatologists and neurologists to distinguish between hepatic encephalopathy and dementia, prioritize abstinence support as the single most impactful intervention, and ensure adequate nutritional care. Keep larsucosterol on your radar as a potential future option, but do not make care decisions based on a drug that has not yet been approved. The science is moving, but it has not yet arrived.
Frequently Asked Questions
Has any drug been FDA-approved for alcoholic liver disease or alcohol-associated hepatitis?
No. As of March 2026, there are zero FDA-approved drugs for alcohol-associated hepatitis. Corticosteroids are used off-label as the standard of care, but they have never received a formal FDA indication for this condition.
What is larsucosterol and how close is it to approval?
Larsucosterol (formerly DUR-928) is an endogenous sulfated oxysterol currently in Phase 3 clinical trials for severe alcohol-associated hepatitis. It has received FDA Breakthrough Therapy and Fast Track designations, but topline results from the pivotal trial are not expected for approximately two years.
What was the drug approved in 2024 for fatty liver disease?
Resmetirom (brand name Rezdiffra) was approved in March 2024 for MASH (metabolic dysfunction-associated steatohepatitis), which is a non-alcoholic fatty liver disease. It has no indication or evidence for treating alcohol-related liver damage.
How does alcoholic liver disease relate to dementia and cognitive decline?
Chronic alcohol-related liver disease can cause hepatic encephalopathy — cognitive impairment resulting from the liver’s inability to clear toxins from the blood. This condition can mimic dementia symptoms and may coexist with or accelerate neurodegenerative disease, making accurate diagnosis essential.
What is the current mortality rate for severe alcohol-associated hepatitis?
Approximately 30 percent of patients with severe alcohol-associated hepatitis die within 90 days of hospitalization, even with the current standard of care including corticosteroid treatment.
What are the most important treatments available right now for alcohol-associated hepatitis?
The cornerstone of treatment remains abstinence from alcohol and nutritional support. Corticosteroids (prednisolone) are the first-line pharmacological treatment for severe cases, though their effectiveness is limited. Liver transplantation is an option for patients who do not respond to medical management but is constrained by organ availability and sobriety requirements.
